1. Home
  2. YHC vs CDIO Comparison

YHC vs CDIO Comparison

Compare YHC & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • YHC
  • CDIO
  • Stock Information
  • Founded
  • YHC 2021
  • CDIO 2017
  • Country
  • YHC United States
  • CDIO United States
  • Employees
  • YHC N/A
  • CDIO N/A
  • Industry
  • YHC Beverages (Production/Distribution)
  • CDIO Biotechnology: Commercial Physical & Biological Resarch
  • Sector
  • YHC Consumer Staples
  • CDIO Health Care
  • Exchange
  • YHC Nasdaq
  • CDIO Nasdaq
  • Market Cap
  • YHC 12.3M
  • CDIO 12.3M
  • IPO Year
  • YHC N/A
  • CDIO N/A
  • Fundamental
  • Price
  • YHC N/A
  • CDIO $0.97
  • Analyst Decision
  • YHC
  • CDIO Buy
  • Analyst Count
  • YHC 0
  • CDIO 1
  • Target Price
  • YHC N/A
  • CDIO $2.00
  • AVG Volume (30 Days)
  • YHC 371.7K
  • CDIO 12.9M
  • Earning Date
  • YHC 04-02-2025
  • CDIO 11-13-2024
  • Dividend Yield
  • YHC N/A
  • CDIO N/A
  • EPS Growth
  • YHC N/A
  • CDIO N/A
  • EPS
  • YHC N/A
  • CDIO N/A
  • Revenue
  • YHC $2,272,001.00
  • CDIO $35,688.00
  • Revenue This Year
  • YHC N/A
  • CDIO $2,081.66
  • Revenue Next Year
  • YHC N/A
  • CDIO $43.84
  • P/E Ratio
  • YHC N/A
  • CDIO N/A
  • Revenue Growth
  • YHC 158.05
  • CDIO 180.90
  • 52 Week Low
  • YHC $0.40
  • CDIO $0.19
  • 52 Week High
  • YHC $3.47
  • CDIO $3.56
  • Technical
  • Relative Strength Index (RSI)
  • YHC N/A
  • CDIO 59.49
  • Support Level
  • YHC N/A
  • CDIO $0.78
  • Resistance Level
  • YHC N/A
  • CDIO $1.31
  • Average True Range (ATR)
  • YHC 0.00
  • CDIO 0.31
  • MACD
  • YHC 0.00
  • CDIO 0.01
  • Stochastic Oscillator
  • YHC 0.00
  • CDIO 46.67

About CDIO Cardio Diagnostics Holdings Inc. Common stock

Cardio Diagnostics Holdings Inc is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company was formed to further develop and commercialize a proprietary artificial intelligence-driven integrated Genetic-Epigenetic EngineTM for cardiovascular disease to become the leading medical technology company for enabling improved prevention, early detection, and assistance in the treatment of cardiovascular disease.

Share on Social Networks: